prasentation Arion Fixed copy

ARION

Strategic Source of Non-Dilutive
Funding

A tool to maximize funding potential

Arion turning non-dilutive funding into a strategic source of funding

Arion leverages its expertise in selecting and significantly
enhancing the success rate of obtaining non-dilutive grant
funding for its clients. In select cases, Arion may also leverage
the success of non-diluting financing to introduce appropriate
clients to the new dynamic DeFi (Decentralize Finance)
blockchain based financing which creates additional financing
opportunities for its clients and partners
Arion

The needs

Capital = the Oxygen of any Business

Capital Raising With dilutive funding, dilutive funding Most entrepreneurs and
Is Inefficient & businesses are called requires a startup founders are
Challenging to think long and hard willingness to familiar with loans,
about the type of sacrifice some mezzanine finance and
investors they attract control over the equity funding and
company’s direction unaware of the funding
as well as a cut of opportunities available
the future profits. to them other than
venture capital like Non
Diluting funding.

Non-Dilutive Funding – A Strategic Financial Tool

Arion has a unique approach to unite innovative companies and
research institutes with non-dilutive project Grants from
Governments and NGO’s (non-profit non-governmental entities),
providing enterprises a strategic source of non-dilutive funding at
critical stages of the business development cycle.

What is non-dilutive funding?

A safe source of project finance without the requirement to
distribute a portion of your company’s share equity to the donor
and often without the need to repay the grant!

The Global Non-Dilutive Funding Market $156B $261B

Non-Dilutive funding us shown to be affective at filling funding 2007 2021
gaps, validating products ideas and returning significant value for
communities. Organizations raised non-dilutive funding have
generated billions in revenue, employed thousands and attracted
hundreds of millions in dollars in follow-up ventures capital.

Non-Dilutive funding market is an expanding source of critical capital for
technology and product developments of companies at all stages of their
life cycle. Companies have leveraged non-dilutive funding to raise
hundreds of millions of dollars in additional needed capital from
traditional private sources and to generate billions in revenues.

Non-Dilutive Funding Market is a of Hundreds of billions of dollars market
with significant growth rate granting by thousands of national and
international sources. For instance:
EU Horizon Europe - European Framework Program allocated from
2021-2027 100 Billion Euro funding for research and innovation.

Arion - A tool to maximize funding potential

Non-Dilutive Funding Benefits Strategic Approach Public
Markets
The challenge is to identify appropriate funding NDF
opportunities and navigating successfully the
process of requesting the funding. The percentage Angels VCs
of successful grant requests is relatively low and
the process itself can be time consuming and
expensive for management.
In particular when a company needs to process
multiple applications to increase its chances of
funding.

Maximize the Company’s
Funding Potential

Arion solution

Arion has developed a sophisticated process to maximize funding
potential, helping companies raise more capital using non-dilutive
funding sources

The Process · Identify the most relevant funding
opportunities
Project Platform Strategy planning and
application writing · strategize to maximize the
appliction’s change of success

· Manage complex project
production processes

· Lead joint application writing

· Support final contract negotiations

Valitation & Smart Submission
Acceptance Contracts

Arion will focus, without limitation, on the market segment Arion estimation based on screening of about 300
with the highest success chances yet with very limited potential projects yearly and select the best 30 projects
available budget to finance the submission process. Meaning, to apply.
start-up companies and research institutes. The two main funding sources is EU grant programs and
Arion will be compensated only for its success thereby US-Federal grant programs with present success rate
limiting the up front costs and risks to its clients. Arion will range of 5%-10%.
receive a fee of 5% to 15% of the amount of the grants Arion track record indicate that we can increase the
awarded to Arion clients after a successful campaign. success rate by at least 2-2.5 times, resulting awarding
Arion business model based on screening the potential 5-10 grants per year with average amount of 2M$ each.
projects of start up companies and research institutes Arion compensation in that case will generate an
through a professional pre-evaluation process in order to average income of 1.5–2M$ per year while the operation
select the projects with the highest chances to award the cost is about 1M$ per year. If a client company desires
grants. For thus projects, Arion experts will develop a long additional services such as secondary DeFi funding
term plan to apply to the most promising funding sources in support the `Parties would agree on a separate
order to maximize the success rate of this projects. consulting fee.

Arion – The Team and Environmental Technology incubator, as a representative of Dow
Chemicals. This vast experience in these fields makes Dr. Even one
Members of Arion management team have led of the top consultants for VCs and other investment vehicles
private and public companies, from inception to interested in cleantech, chemistry and materials, and
global sales. The team includes experts in Venture nanotechnology.
Capital, Legal & Regulatory, Academia & research Dr. Even has participated for 4 years as a member in the Advisory
institutes. Group Expert Risk Finance at the European Commission. He has a
role as team leader for the technology transfer group within this
DR. Eli Even Committee.
Recently, Dr. Even has become a Member of the Israel National
Dr. Eli Even has over 20 years’ experience investing in Committee for International Research & Development Relations,
advanced materials and Cleantech space. Dr. Even Israel Ministry of Science & Technology.
obtained his PhD in Applied Chemistry from the Hebrew
University in Jerusalem. Dr. Even co-founded Terra Jacob Weiss
Venture Partners, an Israeli cleantech VC. Dr. Even
developed his expertise in the local market of renewable Mr. Weiss has extensive experience as a senior executive and
energy, and water and environmental technologies. Dr. General Counsel in large companies as well as active participation in
Even also served as the investment manager at the public financing through NASDAQ for an entrepreneurial high tech
Millennium Materials Technology Fund (MMTF), the only start-up, including: former Director at “Elta” North America; former
Israeli venture capital investment vehicle focused Chairman (and CEO) of ImageSat International; former Legal Director
primarily on investments in new materials. During Dr. of Security Group at “Nice Systems”; and former VP General Counsel
Even's tenure at MMTF, the fund had $52 million under – Israel Aerospace Ltd (IAI).
management, and held a portfolio of 17 mature
companies. These companies focused on advanced Dr. Goldi Kozloski
materials, with applications varying from batteries to life
science and semiconductors. Several investments Goldi A. Kozloski, PhD. Dr. Gold earned a B.S degree in Biology and
identified and nurtured by Dr. Even are among the most Premed from Eckerd College (Magna cum laude), and a Ph.D. in
promising companies in their respective sectors. Dr. Biochemistry and Molecular Biology from the University of Miami
Even also served as the Scientific Director of ATI Water

Miller School of Medicine. Following graduation, he entered a post-doctoral Ehud Spiegel
fellowship at the Sylvester Cancer Center in Miami, FL where he specialized in
hematology-oncology research. Dr. Gold has authored and reviewed dozens of Mr. Spiegel has in the last few years, focused on the ADAS and
grants to the NIH, NSF, NCI, and to foundations and associations. In 2018, he Autonomous Car markets, taking part in the challenges of defining
started a biomedical research consulting firm, Alef Research Strategies LLC, and developing technologies and bringing products to market with
that offers grant consulting services mostly to startups. In this role, he gained car makers and tier-1 producers and integrators. He has gained
experience in NIH Small Business Innovation Research (SBIR) grants, EU significant experience in Computer vision, Scene Perception &
Horizon 2020, EIC phase 2 grants, Israel Innovation Authority (IIA) grants, and Cognition, Sensor Fusion, Mapping, and Architectures. He
American Foundations grants. previously led technology, R&D and go-to-market activities in
companies that developed solutions for Ridesharing, Augmented
Prof. Eli Porat Reality, CDN, Social networks, and more.

Ely Porat completed his PhD in 2001, at the age of 21. Thereafter, in parallel to Noam Mushkin, Ph.D.
acting as section head of a research group during his extended military
service, he was an Assistant Professor at Bar Ilan University and became an A licensed Israeli Patent Attorney with over 20 years of Intellectual
Associate Professor when he was 27 years old. To date, he is the youngest Property Law experience both in private practice and as in-house
professor in Israel. His primary research field is pattern matching, but he has Corporate IP counsel for Adama Agricultural Solutions Ltd. and Vice
also worked on streaming algorithms, data structures, coding theory, group President of IP in the Perrigo Company. Professional experience
testing, compressed sensing and game theory. A big part of his work is includes the development, planning and execution of
interdisciplinary, and he has combined methods from different areas on more comprehensive global IP strategies in support of the business and
than one occasion. R&D goals as well as managing companies' global IP portfolios.
Responsibilities include managing teams of in-house legal
Dana Cohen professionals; coordinating, supporting and managing outside
counsel in litigations, oppositions and preparation & prosecution of
A senior manager (CEO) with vast experience in private and public biotech patent applications globally. Business related aspects of IP
industry companies. She has in-depth and unique knowledge in personalized responsibilities include IP licensing, assessing competitors' IP and
medicine, solid tumors and hematological malignancies diagnostics & due diligence. Academic and scientific background include a Ph.D.
therapeutics, drug monitoring, Radio-pharmaceuticals, molecular diagnostics in Applied Organic Chemistry from the Hebrew University in
technologies and genetic diseases. Ms. Cohen serves as a business mentor of Jerusalem as well as experience as an R&D scientist.
Israeli and USA biotech entities as well as business mentor to Tel Aviv and Bar
Ilan Universities. She has extensive expertise in capital raising, including from
various Israeli and EU governmental funding sources ($10M).

Thank You.